elacridar has been researched along with Hepatitis B Virus Infection in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arnoult, E; Borghys, H; De Pooter, D; Demin, S; Dhuyvetter, D; Embrechts, W; Fanning, G; Herschke, F; Khamlichi, MD; Last, S; McGowan, D; Mostmans, W; Pauwels, F; Pieters, S; Raboisson, P; Scholliers, A; Smyej, I; Stoops, B; Thoné, T; Van Schoubroeck, B; Vlach, J | 1 |
1 other study(ies) available for elacridar and Hepatitis B Virus Infection
Article | Year |
---|---|
Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.
Topics: Animals; Antiviral Agents; Computer Simulation; Cytokines; Dogs; Hepatitis B; Hepatitis B virus; High-Throughput Screening Assays; Humans; Macaca fascicularis; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Pyrimidines; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Toll-Like Receptor 7; Toll-Like Receptor 8; Virus Replication | 2016 |